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Guanine-based purines (GBPs) have been recently proposed to be not only metabolic
agents but also extracellular signaling molecules that regulate important functions in
the central nervous system. In such way, GBPs-mediated neuroprotection, behavioral
responses and neuronal plasticity have been broadly described in the literature.
However, while a number of these functions (i.e., GBPs neurothophic effects) have been
well-established, the molecular mechanisms behind these GBPs-dependent effects
are still unknown. Furthermore, no plasma membrane receptors for GBPs have been
described so far, thus GBPs are still considered orphan neuromodulators. Interestingly,
an intricate and controversial functional interplay between GBPs effects and adenosine
receptors activity has been recently described, thus triggering the hypothesis that GBPs
mechanism of action might somehow involve adenosine receptors. Here, we review
recent data describing the GBPs role in the brain. We focus on the involvement of
GBPs regulating neuronal plasticity, and on the new hypothesis based on putative GBPs
receptors. Overall, we expect to shed some light on the GBPs world since although
these molecules might represent excellent candidates for certain neurological diseases
management, the lack of putative GBPs receptors precludes any high throughput
screening intent for the search of effective GBPs-based drugs.
Keywords: guanine-based purines, guanosine, neuroprotection, synaptic plasticity, purinergic receptors,
adenosine
INTRODUCTION
Guanine-based purines (GBPs), including the nucleotides guanosine 5′-triphosphate (GTP),
guanosine 5′-diphosphate (GDP) and guanosine 5′-monophosphate (GMP), the nucleoside
guanosine (GUO) and the nucleobase guanine (GUA) have been traditionally characterized as
modulators of intracellular processes, especially considering their role in G protein dependent
signal transduction. In the last two decades, GBPs have been also shown to exert extracellular
effects and to act as neuromodulator pleiotropic molecules affecting several cellular processes,
including growth, differentiation and survival, in both the central and the peripheral nervous
system (CNS and PNS, respectively; Schmidt et al., 2007; Rathbone et al., 2008). However,
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despite accumulated experimental evidences supporting
their extracellular role, putative receptor sites have not been
characterized, thus GBPs are still orphan neuromodulators. In
this article, apart from reviewing recent data illustrating the
involvement of GBPs in the nervous system, we especially discuss
the new hypothesis concerning the existence of putative GBPs
receptors.
PURINERGIC SYSTEM AND
“PURINOME”
The term “purinergic system” usually refers to a complex system
composed by purines bases, such as adenine (ADA) and GUA,
their corresponding nucleotides adenosine 5′-triphosphate (ATP)
and GTP, adenosine 5′-diphosphate (ADP) and GDP, adenosine
5′-monophosphate (AMP) and GMP, and nucleosides adenosine
(ADO), inosine (INO) and GUO. In addition, the purinergic
system includes the metabolites xanthine (XAN), hypoxanthine
(HYPO) and uric acid (UA), together with the receptors,
transporters and enzymes involved in purinergic transmission
(Schmidt et al., 2007). Classically, purinergic signaling has
been proposed to be regulated by the interaction of natural
purines with a large number of specific own receptors, by
a complex machinery assuring cell signaling transmission as
well as by purine clarification from the extracellular medium
by ecto-enzymes and/or bidirectional carriers (see below).
Noteworthy, an emerging theory postulates that a broad-
spectrum of direct/indirect interactions also exist within a
cooperative synergic network, defined as “purinome” (Volonte
and D’Ambrosi, 2009). The functions of the purinome involve
the interaction and heteromerization between purinergic and
other receptors. Interestingly, it is nowadays widely accepted
that direct receptor-receptor interactions (i.e., oligomerization)
permit to integrate information from different sources, thus
providing a fine and complex control over various regulatory
mechanisms (Ferre, 2007; Borroto-Escuela et al., 2012; Fuxe
et al., 2012; Di Liberto et al., 2014). Regarding purinergic
receptors, it has been shown, for instance, that adenosine 1
receptor (A1R) heterodimerizes with adenosine 2A receptor
(A2AR), and also with dopamine D1, metabotropic glutamate
mGlu1α, cannabinoid CB1 and adrenergic β1-and β2-adrenergic
receptors, leading to diverse functional outcomes (Gines et al.,
2000; Ciruela et al., 2001, 2006a,b; Chandrasekera et al., 2013).
Recently, based on experimental evidence, Borroto-Escuela
et al. (2014) proposed a network representation of G-protein
coupled receptors (GPCR) heterodimers in the brain, in which
A1R receptor emerges as a hub receptor forming 11 different
heteroreceptor complexes.
EXTRACELLULAR PURINES: THEIR
RELEASE AND RE-UPTAKE.
The extracellular concentration of purines is dependent on
the amount of released purines, on the efficiency of re-uptake
mechanisms and on the activity of extracellular metabolizing
enzymes. Purines can be released to the extracellular space by
both neurons and glial cells, under physiological and, even
more interestingly, in pathological conditions. Adenine-based
purines (ABPs), for example ATP, can be released from neuronal
presynaptic terminals and glial cells (Burnstock et al., 1972;
Wagner et al., 1978; Burnstock, 2006), where they can be used
as substrate for several ectonucleotidases (Zimmermann, 1996;
Bonan, 2012; Zimmermann et al., 2012), which generate multiple
breakdown products (ADP, AMP, and ADO) able to activate
different receptors and to trigger several effects (Zimmermann,
2011).
GTP is co-stored together with ATP in neuronal synaptic
vesicles from which it is released in association with ATP by
exocytosis (Wagner et al., 1978; Santos et al., 2006). On the other
hand, ATP is not involved in the outflow of GTP from glial cells.
Nevertheless, GTP and its di- and mono-phosphate derivatives,
together with the corresponding adenine-based counterparts, are
substrates and thus competitors of the same ecto-nucleotidases
while neurons seem to be able to release very small amounts of
ADO per se, the presence of ADO outside glial cells is mainly due
to the extracellular metabolism of released ATP. There are some
peculiar differences concerning the other ADA- and GUA-based
nucleosides, INO and GUO. Although these nucleosides derive
from the hydrolysis of extracellular Inosine monophosphate
(IMP)/GMP or from ADO deamination (for INO), they would
also be constitutively released from neurons, astrocytes, C6 or
U373 glioma cells, microglial cells or SH-SY5Y neuroblastoma
cells (Ballerini et al., 2005, 2006a,b; Giuliani et al., 2012c).
However, non-physiological and relatively extreme stimulations
(e.g., seizure activity, hypoxia/hypoglycemia, and superfusion
with high K+) seem to be required to elicit ADO eﬄux from glial
cells; accordingly, in such conditions extracellular ADO would be
that escaping from uptake and metabolism, thus representing a
tissue overflow rather than a release per se (Di Iorio et al., 1998).
Finally, regarding purine metabolites such as HYPO, GUA,
and XAN, which can be found in the medium of cultured glial
cells and in the fluid from super-fused brain slices (Rathbone
et al., 1999; Zamzow et al., 2008), it was thought during several
years that they were uniquely transported outside the cells by
specific transporters (NBTs), different from those for nucleosides
(ENTs) (Sinclair et al., 2000; Dos Santos-Rodrigues et al., 2014).
Thus, their presence outside of cells was considered, like for
ADO, the result of cell overflow of substances to be eliminated
(Parkinson et al., 2011). However, these purine metabolites would
still be present in the extracellular milieu of cells treated with
inhibitors of transporters, suggesting that they would also derive
from the extracellular metabolism of nucleosides (Rathbone et al.,
1999; Jiang et al., 2008b; Giuliani et al., 2012a; Caciagli et al.,
2014).
Taken together, the previous findings indicate that the systems
of ABPs and GBPs are physically and functionally present
outside cells, where they operate simultaneously. In addition
some peculiarities deserve to be emphasized. For instance: (i)
the extracellular levels of GBPs are about 2-3-fold higher than
those of their ADA-based counterparts (Ciccarelli et al., 1999);
(ii) the metabolism of ADA and GUA nucleotides maintains
constant the proportions of the components of the two systems;
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however, there are some differences in the respective nucleosides,
such as the presence of only one GUA (GUO) instead of the
two ADA nucleosides (ADO and INO), or the different affinities
of these compounds for the trans-membrane transport systems,
as well as for the enzymes deputed to their metabolism; and
(iii) compared to ADO, the extracellular levels of GUO remain
particularly elevated after an ischemic insult, a fact that has
been shown both in cultured astrocytes (Ciccarelli et al., 1999)
and in a model in vivo of focal cerebral ischemia (Uemura
et al., 1991). To end with, it is important to underline that it
is not an easy task to determine the exact concentrations of
extracellular GBPs. Thus, the most common analytical assays,
such as HPLC or capillary electrophoresis, do not permit
to differentiate some peaks of ADA and GUA compounds,
which are often overlapped (e.g., HYPO and GUA), thus
their quantification cannot be carried out properly. Hence, to
ameliorate the knowledge of GBPs system it is still necessary
to improve the analytical methods, in order to separate these
compounds from the ABPs counterparts (Ito et al., 2000; Stentoft
et al., 2014).
RELEASE OF ENZYMES METABOLIZING
PURINES
It is well known that purine metabolism is mainly oriented
to preserve, by multiple pathways, the levels of triphosphate
nucleotides. The enzyme system regulating the homeostasis of
extracellular purines largely corresponds to that responsible for
the metabolism and salvage of intracellular ABPs and GBPs.
Indeed, it is well known that a broad spectrum of membrane-
bound nucleotidases contribute to the breakdown of extracellular
nucleotides (Zimmermann, 1996; Zimmermann et al., 2012).
Moreover, it has also been recently reported that some soluble
nucleotide kinases are released from cells and contribute to
restore ATP levels when the extracellular amount of AMP
becomes elevated (Yegutkin, 2014). In contrast, no ecto-enzymes
seem to be involved in the catabolism of extracellular ADA- and
GUA-based nucleosides, which would likely and only depend on
some actively released soluble enzymes.
A few number of reports have indicated that some enzymes of
the metabolism of purine nucleosides, such as ADO deaminase,
purine nucleoside phosphorylase (PNP), Guanase and Xanthine
Oxidase (XO), are detectable in plasma (Roberts and Newton,
2004; Roberts et al., 2004; Karabulut et al., 2005; Chittiprol
et al., 2007; Lopez-Cruz et al., 2014; Giuliani et al., 2016).
Furthermore, some of these enzymes have been proposed
as potential diagnostic or prognostic markers for different
pathological conditions. For instance, PNP plasma levels have
been associated with the malignant degree and the diffusion
capability of some tumors, such as the melanoma or pancreatic
adenocarcinoma (Roberts et al., 2004; Vareed et al., 2011);
whereas XO activity, which is physiologically low in plasma and
increases after ischemic events, has been considered predictive for
cardiovascular disease, independently of uric acid plasma levels
(Gondouin et al., 2015; Lopez-Cruz et al., 2014). Nevertheless,
it is still not sufficiently elucidated the origin of these plasmatic
enzymes, the mechanisms by which they are released from cells
and their activity in the metabolism of the extracellular purine
nucleosides, importantly in the proximity of membrane purine
receptors.
Recently, it has been observed, either in cell lines or in primary
cultures of neural cells, that glial cells, especially microglia,
but not neurons are able to constitutively release PNP in the
culture medium. Extracellular K+ or exogenous ATP, but no
other types of cell stimulation, such as LPS or interferon-γ,
enhance, in a dose-dependent manner and via the lysosomal
system, PNP release in the culture medium, where the enzyme
is detectable both as soluble fraction and inside of membrane-
derived vesicles (Polazzi et al., 2011). Interestingly, similar
results have been shown investigating Guanase (Caciagli et al.,
2014). These findings suggest that at least glial cells release the
key enzymes of the metabolism of ABP and GBP nucleosides
into the corresponding bases, which may act as potent cell
damaging pro-inflammatory agents via reactive oxygen species
(ROS) production. Therefore, the complex interplay between the
activity of these enzymes and the transport systems of nucleosides
across membranes may control the cell-specific homeostasis of
extracellular purines as well as their signaling.
In physiological conditions, the activity of these kinds of
enzymes controls the production of purine bases maintaining
their levels in a range of “limited ability” to generate ROS.
This delicate equilibrium seems to be lost during degenerative
processes, which are often associated with chronic inflammatory,
or in hypoxic, events. Hypoxia, for example, by inducing the
over-expression/activity of 5′-nucleotidase and a concomitant
blockade of the PNP activity, accelerates the hydrolysis of
the nucleotides, thus causing a consequent accumulation of
intra- and extra-cellular nucleosides, especially GUO (Ciccarelli
et al., 1999). Similarly, during post-ischemic reperfusion, the
functional block of the PNP seems to be not sufficient,
resulting in the formation of large amounts of purine bases,
whose catalytic oxidation, mediated by XO, produces ROS
that through the activation of Nuclear factor kappa B
(NF-kB) produce pro-inflammatory cytokines (Lorne et al.,
2008).
Noteworthy, further emerging evidences support a relevant
patho-physiological significance for these enzymes, which may
have also some functions independent from their enzymatic
activity. Among these enzymes, it is important to mention
Nucleotidase II (Tozzi et al., 2013), which is currently being
investigated (looking for its putative role outside cells) in our
laboratory. This enzyme seems to interact with the ice protease-
activating factor (IPAF) in order to regulate its folding and
conformation, thus acting as a sensor of the global health
state of the cell, and capable of regulating its death (Cividini
et al., 2015). On its own, Guanase, named also cypin, plays
a trophic role on the development of brain by regulating the
dendritic arborization and neuronal morphology. In addition,
Guanase seems to be involved in the mechanisms responsible of
liver transplant rejection (Fernandez et al., 2010). Overall, the
above-mentioned non-enzymatic activities of enzymes involved
in purine nucleosides may be even more attractive as potential
targets for developing new drugs.
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PURINERGIC RECEPTORS
The present review is mainly focused on GBPs functions.
However, we first provide a short overview of ABPs receptors, in
order to contextualize the current knowledge of GBPs receptors
into the purinergic field.
ABPs Receptors: Long Story Made Short
ABPs play a pivotal role in the modulation of neurotransmission
and neurotrophism acting on two different families of receptors:
P1, activated by ADO, and P2, activated by ATP/ADP
nucleotides. P1 receptor family includes four different subtypes
(A1R, A2AR, A2BR, and A3R) of GPCRs. A1Rs and A3Rs are
typically coupled to Gi proteins and thus inhibit adenylyl cyclases,
whereas A2ARs and A2BRs are coupled to Gs proteins and
increase the production of cyclic AMP (cAMP) (Zimmermann,
2011). P1 receptors are expressed in neurons, astrocytes,
oligodendrocytes and microglia and their stimulation activates
multiple functions, such as synaptic plasticity (Dare et al.,
2007; Burnstock et al., 2011a,b; Zimmermann, 2011; Del Puerto
et al., 2013). The P2 receptors are subdivided in two different
subfamilies: ionotropic and metabotropic receptors (P2XRs
and P2Yrs, respectively). The P2XRs subfamily includes seven
different subtypes, which are mostly expressed by neurons and
astrocytes, and in a lesser extent by oligodendrocytes, Schwann
cells, and microglia. ATP mediated activation of P2XRs enhances
rapid changes in membrane potential by increasing Na+, K+,
and Ca2+permeability (North, 2002; Roberts et al., 2006; Del
Puerto et al., 2013). Thus, they are involved in the regulation of
fast synaptic transmission, synaptic plasticity, and fast neuron–
glia signaling (Silinsky et al., 1992; Pankratov et al., 1998, 2002,
2009; Burnstock et al., 2011a; Lalo et al., 2011a,b). Conversely,
the P2Y subfamily is composed by eight different P2YRs subtypes
(Burnstock, 2007b). Interestingly, while P2Y1R, P2Y2R, P2Y4R,
P2Y6R, and P2Y11R are coupled to Gq proteins and activate
phospholipase C (PLC), the P2Y12R, P2Y13R, and P2Y14R are
coupled to Gi proteins and inhibit adenylyl cyclases (Abbracchio
et al., 2006). Overall, most of these receptors are expressed
in neurons and glial cells, and are involved in bi-directional
neuron–glia communication, thus exerting long-term effects
on proliferation, neurogenesis, differentiation, migration and
apoptosis (Burnstock, 2007a; Neary and Zimmermann, 2009;
Verkhratsky et al., 2009; Del Puerto et al., 2013). For a more
detailed introduction to ABPs receptors biology several well-
documented reviews are available (Burnstock, 2007a,b; Burnstock
et al., 2011a,b).
GBPs Receptors: Short Story Made Long
At present, despite the plethora of experimental evidences
pointing to the existence of putative GBPs receptors in the brain,
a specific receptor has not been still identified; accordingly,
GBPs are orphan neuromodulators. However, a number of
cellular effects of GBPs might only be explained by the
activation of different extracellular binding sites, since most
of them still persist in the presence of inhibitors of GBPs
transporters (Gysbers and Rathbone, 1992; Di Iorio et al.,
2004). Actually, specific binding sites for GTP in PC12 cells
(Gysbers et al., 2000) and the presence of a single high affinity
binding site for [3H]-GUO in rat brain membranes (Traversa
et al., 2002, 2003) have been described, supporting the possible
existence of GBPs transmembrane receptors. GUO binding on
rat membranes is saturable, reversible and is not displaced by
other naturally occurring purines, such as ADO, HYPO, XAN,
caffeine, theophylline, GDP, GMP, and ATP, thus suggesting that
this binding site does not involve receptors for ABPs (Traversa
et al., 2002). Indeed, GUO or GTP do not bind with high-affinity
to ABPs receptors (Muller and Scior, 1993). The available data is
in agreement with the fact that GBPs, in particular GUO, bind
to metabotropic receptors and that many effects of GBPs are
mediated through G protein-dependent signaling pathways; it
has been shown, for instance, that the pertussis toxin-mediated
inhibition of Gi/Go-protein reverses some of the effects of GUO
on cell viability and glutamate uptake in hippocampal slices
(Dal-Cim et al., 2013). Furthermore, by monitoring the binding
of a non-hydrolysable-labeled GTP, it has been demonstrated
that GUO is able to activate a putative not yet identified
GPCR, different from the well-characterized ADO receptors, in
rat brain membranes, (Volpini et al., 2011). Interestingly, we
were able to obtain similar results, since we determined the
activation of a putative unknown GPCR for GUO by means of
binding experiments and in situ autoradiography of [35S]GTPγS,
respectively, in membranes and slices from rat brain (Grillo et al.,
2012).
In addition to the above-mentioned data showing the
existence of a putative unknown GPCR for GBPs, other findings
also indicate that GUO may signal through A1R and/or A2AR
(Figure 1). For example, it has been observed that GUO
protects hippocampal slices against oxidative and inflammatory
processes in an A1R dependent manner, while GUO-induced
neuroprotection and stimulation of glutamate uptake involves
A2AR activation (Dal-Cim et al., 2013). A1R blockade or
A2AR activation can reverse GUO-evoked neuroprotective effect,
suggesting that GUO effect may involve an interaction with A1R-
A2AR oligomers (Lanznaster et al., 2016). Furthermore, GUA
inhibition of renal Na+-ATPase activity, which is dependent
on the activation of a Gi-coupled receptor, is blocked by
antagonists of A1R (Wengert et al., 2011). In addition, while
P2 receptor antagonists significantly reduce the stimulation of
cell proliferation induced by GTP, a preferential A2BR antagonist
only partially decreases the mitogenic activity of GUO in
astrocytes (Ciccarelli et al., 2000). Overall, these data could
suggest that GUO, probably with low affinity, may also bind
to ADO receptors and act as an agonist, triggering alternative
pathways to those promoted by ADO. However, it is needed
to say that GUO binding to ADO receptors cannot account
for all GUO-mediated effects in brain, since many of them
still persist in the presence of both P1 and/or P2 receptor
antagonists (Gysbers and Rathbone, 1992; Tasca and Souza,
2000; Frizzo et al., 2001). Indeed, the neuritogenic activity of
GTP is not reproduced by ADA nucleotides, whereas the GUO
effect is synergistic with that produced by A1R/A2R agonists
and it is P1 receptors independent, since it is not inhibited by
A1R/A2R antagonists (Gysbers and Rathbone, 1996a). Overall,
these results support either the existence of specific GPCRs for
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GUO and/or of receptor heterocomplexes between GUO and
ADO receptors (Figure 1). This functional interplay between
GUO and ADO suggests that putative GUO receptors might
share some particular features, yet elusive to current experimental
approaches, with ARs, or alternatively that they might form
heterocomplexes with ARs modulating the reciprocal activity
(Figure 1). Finally, an additional theory, according to the
hypothesis previously reported (Ciruela, 2013), consists of the
no existence of putative GUO receptors, thus this molecule
would signal through existing receptor complexes containing
A1R and/or A2R (Figure 1). The elucidation of the mechanism
of GUO and ADO receptors interaction and the characterization
of membrane-binding sites are under current investigation in our
laboratory. Overall, these possibilities may partially explain as
to why GUO receptors have not still been identified, but they
may also spur research to explore among both cloned known
(i.e., ARs) and orphan GPCRs to find a potential specific GUO
receptor. To this aim, good GPCR candidates to explore as
potential GUO receptors could be GPR174/LPS3 (Civelli et al.,
2013), showing high homology with P2Y10, and GPR23/LPA4,
which shares high homology with human P2Y5 receptor and
seems to be a potential putative GUO receptor, as suggested
by preliminary data. (Di Liberto et al., 2012; Lanznaster et al.,
2016). In addition, based on the evidence that ADO receptors,
mainly A1R and A2R, form heteroreceptor complexes with
several members P2Y receptor family (Borroto-Escuela et al.,
2014) and on the high-sequence homology between GPR23 and
P2Y5 receptors, it is reasonable to hypothesize an interaction
between GPR23 and ADO receptors.
GBPs AND CELL SIGNALING
As stated above, several effects of GUO are mediated through
the binding to unknown GPCRs, and therefore dependent
on cell signaling pathways (Gysbers and Rathbone, 1996a,b;
Traversa et al., 2003). Indeed, extracellular GUO enhances the
neuritogenic effects of nerve growth factor (NGF) on PC12
cells through both cAMP-dependent (Gysbers and Rathbone,
1992; Gysbers and Rathbone, 1996a,b; Bau et al., 2005), and
cAMP-independent mechanisms, such as the stimulation of
soluble guanylate cyclase and the increase of intracellular
cyclic GMP (cGMP; Bau et al., 2005). GUO is also able
to stimulate, in vitro, neural stem cell proliferation by
activating the cAMP response element binding (CREB) pathway
(Su et al., 2013), whereas it protects hippocampal neurons
against glutamate-induced cell death by a mechanism that
involves the Phosphoinositide 3-kinase (PI3K)/Protein kinase B
(PKB/Akt)/Glycogen Synthase Kinase3β (GSK3β) pathway (Molz
et al., 2011). Similarly, in C6 glioma cells, GUO protects
against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity
through the activation of the survival pathways regulated
by extracellular signal-regulated kinases (ERK) and PI3K/Akt
(Giuliani et al., 2015). As well, GUO is protective in different
in vitro models against hypoglycemia by modulating oxidative
and nitrosative stress and astroglial responses, such as glutamate
uptake through different signaling involving protein kinase
C (PKC), PI3K, p38, and ERK pathways (Quincozes-Santos
et al., 2013). Additionally, GUO prevents in hippocampal
slices mitochondrial membrane depolarization, inhibits (NF-kB)
activation and reduces inducible nitric oxide synthase (iNOS) and
ROS production via PI3K and mitogen-activated protein kinases
(MAPK)/ERK (Dal-Cim et al., 2013). Also, it is neuroprotective
against mitochondrial oxidative stress in neuroblastoma SH-
SY5Y cells via PI3K/Akt/GSK-3β pathway (Dal-Cim et al.,
2012). Again, anti-inflammatory effects of GUO on microglia
are mediated by activation of the PI3K/Akt/MAPK (ERK1/2 and
p38) pathways (D’Alimonte et al., 2007). Finally, GUO, even
administered in vivo for a systemic treatment, is able to produce
antidepressant-like effects, dependent on the modulation of
NMDA receptors and mediated by cGMP and PI3K/mammalian
target of rapamycin (mTOR) pathways (Bettio et al., 2012,
2014). Taken together, these data generated in different
experimental models, mainly in in vitro studies, point out
intracellular signaling events promoted by GUO and involving
cAMP pathway as well as those linked to the PI3K and
MAPK system. All these evidences may indirectly support the
possibility that GBPs, particularly GUO, may activate cell surface
receptors.
GBPs AND NEUROPROTECTION
Many studies have demonstrated that GBPs are able to exert
neuroprotective effects on a wide variety of cell cultures
and in vivo models (Schmidt et al., 2007; Ribeiro et al.,
2015). These effects would be elicited through three main
actions: by counteracting glutamate excitotoxicity; by preventing
or attenuating neuroinflammation; by counteracting oxidative
stress. In this part of the review we summarize recent research
data investigating the neuroprotective effects of GBPs. Of note,
we are not dealing here with the scarce clinical therapeutic
available data.
Neuroprotection against Glutamate
Toxicity
Different in vivo ischemic models have been used to show the
neuroprotective role of GBPs, including oxygen and glucose
deprivation, hypoxia models and in vivo transient and permanent
ischemic stroke (Ribeiro et al., 2015). Generally, in ischemia
conditions, glutamate released from neurons and astrocytes
in the extracellular space, together with the ischemia-induced
neuronal depolarization, leads to an abnormal neuronal firing
and increased intracellular Ca2+ concentration with a subsequent
loss of synaptic function and cell death (Brassai et al., 2015).
In these models, the neuroprotective action of GBPs against
glutamate toxicity and related intracellular signaling has been
extensively characterized. In such way, it has been reported that
GUO nucleotides, such as GTP, GDP and GMP, are able to
inhibit NMDA-induced neurotoxicity in cultured hippocampal
and neocortical neurons (Morciano et al., 2004), and that
GMP is neuroprotective against glutamate or oxygen/glucose
deprivation-induced neurotoxicity and against NMDA-induced
apoptosis in hippocampal slices (Molz et al., 2005, 2008; Chang
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FIGURE 1 | Schematic representation of interplay between guanosine (GUO) and adenosine (ADO) binding to receptors: GUO binds to ADO receptor
(A1R and A2AR) in competitive manner with ADO (1); GUO binds to putative unknown GUO receptor (2), which may form heterocomplexes with ADO
receptors (3). Several effects of GUO are dependent on cell signaling pathways downstream of receptors (e.g., cAMP/ Protein Kinase A (PKA), PI3K/Akt,
PKC/MAPK, and cGMP), culminating in functional cell responses such as cell proliferation, survival, neuritogenesis, neuroprotection, and cell migration.
et al., 2008). Furthermore, in hippocampal slices and SH-
SY5Y cells exposed to oxygen/glucose deprivation, GUO is
neuroprotective against glutamate induced excitotoxicity via
PI3K/Akt/GSK3β pathway and attenuates glutamate uptake
impairment by promoting the activation of K+ channels and
activating Gi/Go-proteins-coupled signaling (Dal-Cim et al.,
2011, 2012, 2013). In addition, there is evidence that GUO is
effective in counteracting the glutamate toxicity, thus preventing
most of the effects promoted by hyperprolinemia, such as
alteration of glutamatergic homeostasis due to a reduction of
glutamate uptake and coupled to a decrease of membrane Na+,
K+-ATPase activity and of intracellular ATP levels (Ferreira
et al., 2012). As well, GUO increases glutamate uptake in
hippocampal slices of neonatal rats exposed to a hypoxic-
ischemic insult (Moretto et al., 2009). Similarly, it has been
shown that GUO protects hippocampal neuron against ischemia
induced by bilateral common carotid artery occlusion (Ganzella
et al., 2012), decreases infarct volume and improves neurological
function following ischemic stroke in rats (Rathbone et al., 2011).
Also, GUO has been shown to protect neurons against cortical
focal ischemia (Hansel et al., 2014, 2015) and prolong rat survival
by decreasing neurological deficits following transient middle
cerebral artery occlusion (Chang et al., 2008; Connell et al.,
2013). Finally, GUO shows marked anticonvulsant/antiepileptic
effects in several models of epilepsy (Kovacs et al., 2015a). For
example, GUO and other GBPs attenuate the lipopolysaccharide-
evoked increase in spike-wave discharges number in rats (Kovacs
et al., 2015a,b). Also, GBPs are able to prevent seizures (de
Oliveira et al., 2004; Schmidt et al., 2005) or to counteract
electrophysiological spectral changes, including glutamate store
into synaptic vesicles, in a quinolinic acid-induced seizure model
(Tavares et al., 2005, 2008; Torres et al., 2010). Taken together,
the reported data indicate that GBPs exert a neuroprotective
action against glutamate toxicity and that many of the related
effects on the glutamatergic system are produced by increasing
astrocytic glutamate uptake (de Oliveira et al., 2004; Frizzo et al.,
2005; Moretto et al., 2005; Schmidt et al., 2007), thus avoiding
excitotoxic glutamate accumulation (Deutsch et al., 2008). Since
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this neuroprotective mechanism is largely accepted, it has been
suggested the development of GBPs for the treatment of disorders
associated with glutamate excitotoxicity (Deutsch et al., 2005).
Neuroprotection against
Neuroinflammation-Induced Neuronal
Damage
Neuroinflammation is known to contribute to neuronal
damage in different noxious brain conditions (Allan and
Rothwell, 2003). Thus, the GBPs role in preventing or
attenuating neuroinflammation has been extensively studied.
In this context, GUO is able to prevent lipopolysaccharide-
induced pro-inflammatory response and oxidative stress in
hippocampal primary astrocytes through activation of the Heme
Oxygenase-1 (HO-1) pathway and independently of ADO
system (Bellaver et al., 2015). Also, in focal cerebral ischemia
model, GUO administration reduces pro-inflammatory and
increases anti-inflammatory cytokine levels with reduction
of microglial/macrophage cell number, leading to a decrease
in neuronal damage and infarct volume with a positive effect
in functional recovery (Hansel et al., 2015). Additionally,
GUO has been shown to be neuroprotective in an ischemic
stroke model, by inhibiting proinflammatory interleukin-8
(Connell et al., 2013), and to be able to protect hippocampal
slices against inflammatory processes induced by combined
glucose and oxygen deprivation, via a mechanism that involves
MAPK/ERK and A1R activation (Dal-Cim et al., 2013). Finally,
systemic administration of GUO following spinal cord injury
in rats significantly improves motor and sensory functions,
in association with attenuation of the inflammatory response
and apoptotic cell death, and with an increase in sparing of
axons and myelin preservation (Jiang et al., 2008a). Taken
together, the neuroprotective effects exerted by GBPs against
neuroinflammation support the existence of a combined activity
of these compounds on both neurons and glial cells, particularly
microglia cells, as already well shown for ABPs.
Neuroprotection against Reactive
Oxygen Species
Oxidative stress can be defined as an increase of pro-oxidative
mechanisms due to a disturbance of the equilibrium between
pro-oxidant and anti-oxidant systems, which leads to the
production of peroxides and free radicals that damage all
the cell components, including proteins, lipids, and DNA
(Kohen and Nyska, 2002). A large number of experimental
data support a sustained role of GBPs in neuroprotection
against oxidative stress in different in vivo and in vitro models.
For instance, in cortical brain slices, GUO is neuroprotective
against methylmercury-induced oxidative stress (Roos et al.,
2009), and it is also able to prevent the increase in oxidative
damage as well as in the levels of glutamate in a rat model
of chronic hepatic encephalopathy (Paniz et al., 2014). In C6
glioma cells, GUO is neuroprotective against hypoglycemia
by modulating oxidative and nitrosative stress and astroglial
responses, such as glutamate uptake, glutamine synthetase
activity and glutathione levels (Quincozes-Santos et al., 2013).
Similarly, GUO protects SH-SY5Y neuroblastoma cells against
β-amyloid toxicity, by decreasing the formation of early ROS
(Pettifer et al., 2004; Tarozzi et al., 2010) and against the
mitochondrial oxidative stress, induced by the blockage of
mitochondrial complexes, by inducing HO-1 via PI3K/Akt/GSK-
3β (Dal-Cim et al., 2012). Also, in hippocampal slices GUO
reduces ROS production, prevents mitochondrial membrane
depolarization, inhibits NF-kB activation and reduces iNOS
following oxygen/glucose deprivation (Dal-Cim et al., 2013).
GUO neuroprotection against glutamate-induced cell death
mediated by the inhibition of iNOS has been further documented
in hippocampal neurons (Molz et al., 2011). GUO may also
be effective in attenuating the MPP+-induced collapse of
mitochondrial transmembrane potential and in preventing the
subsequent activation of caspase-3, thus protecting dopaminergic
neurons against mitochondrial stress-induced damage (Li et al.,
2014). In addition, in in vivo studies, GUO is able to reduce
hippocampal oxidative damage in rats submitted to sepsis by
cecal ligation and perforation (Petronilho et al., 2012), in which
it also causes a recovery of memory impairment, and in mice
submitted to acute restraint stress, in which GUO produces
antidepressant-like effects (Bettio et al., 2012). Furthermore, in
focal cerebral ischemia model, GUO administration reduces ROS
levels and increases superoxide dismutase levels in the brain,
leading to a decrease in neuronal damage and infarct volume with
a positive effect in functional recovery (Hansel et al., 2015).
Taken together all the described findings strongly suggest a
relevant neuroprotective role of GBPs in the mammalian brain,
providing new targets and strategies for the treatment of brain
diseases.
BEHAVIORAL RESPONSE TO GBPs
Guanine-based purine effects on behavioral response have
been investigated with the limit imposed by the lack of
specific receptors and thereby available antagonist compounds.
Noteworthy, systemic treatments show that GUO, even at high
doses, does not induce mortality and any obvious behavioral
disturbances, such as alterations of coordination, locomotion,
body weight, and core temperature. Additionally, GUO does
not produce depressant activity but rather excitant effects that
resembles those caused by some ARs antagonists (El Yacoubi
et al., 2003; Vinade et al., 2003; Schmidt et al., 2010). On the other
hand, in memory tests in rats, GUO pre-training administration
is amnesic on inhibitory avoidance task (Roesler et al., 2000;
Vinade et al., 2003, 2004, 2005; Saute et al., 2006). This amnesic
effect is compatible with inhibition of glutamatergic system and
seems to be independent from A1R and A2R activation, since
it is not inhibited by the ADO receptor antagonist caffeine
(Vinade et al., 2004, 2005). This GUO effect on memory is also
present after chronic administration with anticonvulsant doses
of this nucleoside and, again, it is not blocked by ADO receptor
antagonists (Vinade et al., 2003, 2004). Additionally, GMP is
able to counteract the facilitatory effect of post-training intra-
hippocampal glutamate administration on inhibitory avoidance
task (Rubin et al., 1996). In contrast, in a different memory model,
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GUA seems to prevent the amnesic effect caused by L-NG-nitro-
L-arginine methyl ester (L-NAME), an inhibitor of NOS (Giuliani
et al., 2012b).
Regarding studies concerning motor behavior, it has been
shown that GUO does not modulate spontaneous locomotion
(Tort et al., 2004), but decreases locomotor activity in the open
field test (Vinade et al., 2005). Also, it has been described that
GUO improves motor behavior both in rats with parkinsonism,
by decreasing bradykinesia (Su et al., 2009), and in rats with
spinal cord injury (Jiang et al., 2007). Interestingly, GUO is
able to produce antidepressant-like effects evaluated by means
of the forced swimming test and the tail suspension test in mice.
This behavioral effect would be dependent on the modulation of
NMDA receptors, nitric oxide-cGMP and PI3K/mTOR pathways
(Bettio et al., 2012, 2014). Additionally, systemic administration
of GMP induces anxiolytic-like behavior in rats (Almeida et al.,
2010). This anxiolytic-like effect of GBPs is further supported
by data showing that chronic administration of GUO in mice
exhibits an anxiolytic effect in the hole board task (Vinade
et al., 2003), in the tail suspension test and in the open field
test (Bettio et al., 2016). Similarly, acute GUO administration
has also been shown to induce robust anxiolytic-like effects.
Of note, pretreatment with caffeine completely abolishes GUO
anxiolytic effects (Almeida et al., 2016). Noteworthy, preliminary
experiments in our laboratory confirm the anxiolytic effect
of GUO in three different behavioral tests in rats: light/dark,
elevated plus-maze and open field (personal observations). All
these behavioral data support an anxiolytic effect of GBPs, in
particular of GUO, which is opposite to the depressant action of
AR activation (Krugel, 2015). However, in several of the reported
investigations, it is not clear the A1R and A2AR involvement
in the behavioral outcomes following GUO treatment (Roesler
et al., 2000; Vinade et al., 2004). Therefore, this issue needs
further investigations, which should take into account other
possibilities (see the GBPs receptor section, e.g., GUO may bind
to heteroreceptor complexes).
NEURONAL PLASTICITY MEDIATED BY
GBPs
To deal with the effects of GBPs on neural plasticity we have
grouped the existing experimental data in the following four
subjects: cell proliferation; neurite growth; synaptogenesis and
synaptic activity; and synaptic plasticity.
Cell Proliferation
Cell proliferation mediated by GBPs has been largely investigated
in glial cells and in a lesser extent in neuronal cells.
Concerning this latter aspect, it has been shown that GBPs exert
antiproliferative effects in human SH-SY5Y neuroblastoma cells
by inducing a S-phase cell-cycle arrest, with up-regulation of
genes for S-phase entry (Cyclin E2) and down-regulation of
genes promoting cell-cycle progression, such as the cyclin B1/B2
that prevents S-phase exit (Guarnieri et al., 2009). By contrast,
GUO is able to stimulate in vitro neural stem cell proliferation
by activating the cAMP-CREB pathway (Su et al., 2013) and to
potentiate neurogenesis in the subventricular zone in a rat model
of parkinsonism (Su et al., 2009). Chronic treatment of mice for
21 days with GUO results in a significant increase in the number
of immature neurons in the ventral hippocampal, which is known
to regulate emotional and motivational behaviors (Bettio et al.,
2016). Finally, GMP or GUO treatment of co-culture cerebellar
neurons/astrocytes would not induce proliferation of neurons or
astrocytes although it promotes MAPK activation (Decker et al.,
2007).
Differently from data available on neurons, evidences pointing
to mitogenic effects of GBPs on astrocytes are broad. The first
result, already published in 1991, showed that GUO, GMP, GDP
and GTP are able to increase cAMP and to stimulate astroblast
proliferation through, at least in part, the enhancement of ADO
extracellular levels (Kim et al., 1991; Rathbone et al., 1991;
Ciccarelli et al., 2000). In this context, GUO has also been shown
to stimulate astrocytes proliferation by producing large amounts
of neuroprotective factors (Rathbone et al., 1999; Ciccarelli
et al., 2001). Also, it has been observed that the mitogenic
effects of GUO on astrocytes is significantly enhanced by the
co-presence in the culture of microglial cells releasing soluble
factors (Ciccarelli et al., 2000). Additionally, after spinal cord
injury, chronic treatment with GUO increases remyelination
by increasing proliferation and differentiation of endogenous
adult oligodendroglial progenitor cells (Jiang et al., 2008a). In
contrast with data suggesting a positive role of GBPs in the
regulation of glial cell proliferation, Garozzo et al. (Garozzo
et al., 2010) have demonstrated that GBPs (GUO, GMP, and
especially GUA) exert a marked growth inhibition in standard cell
culture conditions, on the U87 and U373 glioma cell lines and
on other cancer cell lines, by decreasing the rate of progression
through the S-phase. Interestingly, this antiproliferative effect
is antagonized by ABPs and it is in part dependent on the
intracellular hypoxanthine-guanine phosphoribosyltransferase,
an enzyme responsible for the conversion of GUA into GMP,
suggesting the central role of the intracellular metabolism of
GUA for these inhibitory effects on cell proliferation (Garozzo
et al., 2010). A similar antiproliferative effect has been observed
in human SH-SY5Y neuroblastoma cells following GTP or GUO
treatment (Guarnieri et al., 2009). Taken together, the opposite
effects of GUO on cell proliferation may be dependent on the
experimental model and cell lines used, which subsequently
can lead to the activation of different GBPs binding sites or
receptor–receptor interactions, and consequently to different
functional outcomes. Nevertheless, taking into consideration that
GBPs exert antiproliferative effects in brain cancer cell lines, it
would be relevant to underline the possible anti-tumoral effect
exerted by GBPs. In our opinion, this aspect deserves further
investigation.
Neurite Outgrowth
GBPs are able to play significant neurotrophic roles by
stimulating synthesis and secretion of trophic factors, in both
neuronal and glial cells, and also by inducing cell differentiation,
including neuritogenesis (Schmidt et al., 2007; Rathbone et al.,
2008). Extracellular GUO not only stimulates neurite outgrowth
in primary cultures of rat hippocampal neurons and in
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pheochromocytoma PC12 cells (Gysbers and Rathbone, 1996b;
Rathbone et al., 1999), but also it enhances the neuritogenic
effects of NGF on PC12 cells through both cAMP-dependent
and -independent mechanisms (Gysbers and Rathbone, 1996a,b;
Bau et al., 2005). In the same cell culture model, GTP may
also enhance, by increasing intracellular Ca2+, NGF-dependent
neurite outgrowth (Gysbers and Rathbone, 1996a; Gysbers et al.,
2000). In human SH-SY5Y neuroblastoma cells, both GUO and
GTP induce an increase in the number of neurites as well as
in neurite length, and they also promote cell differentiation
(Guarnieri et al., 2009). Finally GUO, although in a less extent
than ADO, counteracts axonal degeneration following axotomy
in cultured dorsal root ganglia neurons (Press and Milbrandt,
2009). All these effects on neurites growth are probably linked
to a GBPs direct role in the regulation of neurotrophic factors
expression and release (Schmidt et al., 2007; Rathbone et al.,
2008). Indeed, GUO and GTP enhance in astrocytes cultures
the synthesis and release of NGF, fibroblast growth factor-2
and transforming growth factor β (Middlemiss et al., 1995;
Rathbone et al., 1999; Ciccarelli et al., 2001; Schmidt et al.,
2007).
Synaptogenesis and Synaptic Activity
In addition to neuritogenesis, GUO may play a role in
synaptogenesis. In fact, in vivo administration of GUO to
the rat visual cortex promotes an increase in the number
and size of synaptic buttons along the axonal branches
projecting from the rat visual cortex to other cortical areas
and to subcortical structures (Gerrikagoitia and Martinez-Millan,
2009). Interestingly, GUO may also increase cholesterol effiux
and apolipoprotein E expression in astrocytes, through the
PI3K/ERK1/2 pathways (Ballerini et al., 2006a), which have been
demonstrated to promote the development of new synapses in
retinal ganglion cell cultures (Goritz et al., 2005). We think that
this interesting GBPs effect on synaptogenesis deserves more
attention and more molecular approaches.
Concerning GBPs role in neuronal synaptic activity, it
is known that GTP is stored in synaptic vesicles and co-
released with ATP by exocytosis (Wagner et al., 1978;
Santos et al., 2006). Also, indirect evidences indicate that
GUO can be released from neurons following depolarization
(Fredholm and Vernet, 1979). However, as already stated
above, glial cells are the principal source of extracellular GUO,
in both physiological and pathological conditions (Ciccarelli
et al., 1999). GUO may also accumulate extracellularly as
a result of both metabolism of extracellular nucleotides, by
ectonucleotidases, and transport from the cytoplasm through
the bi-directional nucleoside transporters (Schmidt et al., 2007).
Once in the extracellular space, GBPs may interact with neurons
at the synaptic level. However, the role of GBPs, both as
neurotransmitters or neuromodulators, is poorly understood
due to the above-mentioned fact that their putative own
receptors are still unknown. Nevertheless, GBPs appear to
interfere with prejunctional acethylcoline release in the circular
muscle layer of mouse colon, and their effects are dependent
on their cellular uptake and independent from ABP receptors
(Zizzo et al., 2011). Furthermore, GUO is able to induce
muscular relaxation; this effect is dependent on GUO cellular
uptake, adenylyl cyclase activation and increase in cAMP
intracellular levels, while it is independent of neural action
potentials, ARs and K+ channel activation (Zizzo et al., 2013).
In several experimental conditions GBPs seem to modulate
glutamatergic neurotransmission. Indeed, GBPs prevent cell
responses to excitatory amino-acids by blocking glutamate and
AMPA binding in membrane preparations without interacting
with G-proteins (Souza and Ramirez, 1991; Paz et al., 1994;
Tasca et al., 1995, 1998; Dev et al., 1996; Migani et al., 1997;
Porciuncula et al., 2002). Also, GBPs may inhibit membrane
ion currents induced by NMDA (Paas et al., 1996) or kainate
(Rubin et al., 1996; Poulopoulou and Nowak, 1998). These
effects suggest that GBPs may exert a competitive inhibitory
mechanism, acting as antagonists of ionotropic glutamate
receptors, thus antagonizing glutamatergic neurotoxicicity, as
already discussed in a previous section. Furthermore, GBPs show
anti-epileptic activity not only by inhibiting lipopolysaccharide-
evoked increase in spike-wave discharges (Kovacs et al.,
2015a,b) but also by counteracting electrophysiological spectral
changes, including glutamate storage into synaptic vesicles
(Tavares et al., 2005, 2008; Torres et al., 2010), and by
preventing seizures (de Oliveira et al., 2004; Schmidt et al.,
2005).
On the other hand, there are evidences supporting that, at
high doses, GMP may induce activation of ionotropic glutamate
receptors and inhibition of glutamate transporters activity (Molz
et al., 2009). Furthermore, antinociceptive effects have been
observed after systemic administration of GUO, which would
be linked to the modulation of non-NMDA glutamate receptors,
either by means of a direct interaction with receptors or
with their signal transduction mechanisms (Schmidt et al.,
2008, 2010). Finally, GUO has also been shown to modulate
glutamate transporters activity by decreasing glutamate uptake
into synaptic vesicles. Therefore, it would modulate the amount
of transmitter inside the vesicles, which might influence synaptic
strength as well as vulnerability to neural damage processes, by
decreasing the amount of glutamate released to the synaptic
cleft (Tasca et al., 2004). Overall, the above-mentioned works
largely support the modulatory role of GBPs at the glutamatergic
synaptic level. However, further investigations are needed, in
particular regarding the modulation of other neurotransmitters
by GBPs.
Synaptic Plasticity
In contrast to the large body of data existent supporting the
regulation exerted by ABPs on synaptic plasticity through their
broad family of receptors, very little is known, at present, about
the GBPs role in synaptic plasticity. The principal reason of
this limitation is consists, as broadly repeated, of the lack of
known receptor(s). Consequently, it has not been possible the
discovery and use of selective agonists/antagonists. Importantly,
these compounds would be crucial for determining the exact
role of GBPs in various body compartments, including the
CNS. Nevertheless, despite this limitation, it has been possible
to assess, as described above, the modulation of glutamatergic
neurotransmission by GBPs in several experimental conditions,
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which is known to be relevant in synaptic plasticity. Noteworthy,
the effects of GBPs on glutamatergic system are mainly attributed
to the increase in astrocytic glutamate uptake, or to interference
with the function of ionotropic glutamate receptors. However,
no data is available supporting direct neuronal presynaptic
modulation of glutamate release. Indeed, GBPs block glutamate
and AMPA binding in membrane preparations (Souza and
Ramirez, 1991; Paz et al., 1994; Tasca et al., 1995, 1998; Dev et al.,
1996; Migani et al., 1997; Porciuncula et al., 2002). Also, GBPs
inhibit membrane currents induced by NMDA (Paas et al., 1996)
or kainate (Rubin et al., 1996; Poulopoulou and Nowak, 1998), as
well as prevent seizures (de Oliveira et al., 2004; Schmidt et al.,
2005). Finally, it has also been shown that GMP, at high doses,
induce activation of ionotropic glutamate receptors (Molz et al.,
2009). Taken together, the actual experimental data suggest that
GBPs may play a role on synaptic plasticity by modulating, in
different ways, the glutamatergic system.
CONCLUSION AND OUTLOOK
In the present article, we have extensively summarized the
present data concerning the role of the GBPs system in
regulating neuronal function and plasticity. On the other hand,
we have also briefly discussed the scarce knowledge regarding
the mechanisms of action of these orphan neuromodulators.
However, we would not like to simply conclude with the
habitual sentence, classically reported in previous reviews on
this issue, encouraging the scientific community to advance
in GBPs research. Thus, it is clear that further work is still
necessary to elucidate the mechanisms of action of GBPs, this
is, the cloning of specific receptors and characterization of
second messengers related to their extracellular effects. But this
review has been conceived and carried out with the purpose
of acquiring a new consciousness. We honestly think that
research aiming the identification of GBPs receptors may be
based on a recent suggestion (Ciruela, 2013) and our preliminary
data, evidencing that GUO is somehow linked to ARs. Thus,
cooperative efforts should be directed to explore both new
GBPs putative receptors and their possible interplay, especially
in terms of oligomerization and/or allosteric modulation, with
ARs, and also the possible direct binding of GBPs to ARs.
Overall, a very exciting work is expected to be completed,
in a cooperative and collaborative way, in the next years in
order to fill this “big gap” in the purinergic transmission
field.
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